2023
An international research agenda for clozapine-resistant schizophrenia
Luykx J, Gonzalez-Diaz J, Guu T, van der Horst M, van Dellen E, Boks M, Guloksuz S, DeLisi L, Sommer I, Cummins R, Shiers D, Lee J, Every-Palmer S, Mhalla A, Chadly Z, Chan S, Cotes R, Takahashi S, Benros M, Wagner E, Correll C, Hasan A, Siskind D, Endres D, MacCabe J, Tiihonen J. An international research agenda for clozapine-resistant schizophrenia. The Lancet Psychiatry 2023, 10: 644-652. PMID: 37329895, DOI: 10.1016/s2215-0366(23)00109-8.Peer-Reviewed Original ResearchConceptsClozapine-resistant schizophreniaQuality of lifeTreatment optionsTreatment-resistant symptomsThird of patientsNew treatment optionsHealth care providersMiddle-income countriesFunctional outcomeInterventional studyUnmet needEpidemiological researchTranslational approachDiagnostic testsPatientsSchizophreniaHealth policyEarly detectionOptionsSymptomsDiagnosisTrialsAssociations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls
Lin B, Vermeulen J, Bolhuis K, Chang X, Schirmbeck F, van Eijk K, investigators G, Alizadeh B, Bartels-Velthuis A, van Amelsvoort T, Bruggeman R, Cahn W, de Haan L, Rutten B, Guloksuz S, Luykx J, van Os J, Simons C, van Winkel R, Guloksuz S, Blankers M, van den Brink W, de Haan L, Luykx J. Associations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls. Psychiatry Research 2023, 323: 115143. PMID: 36948018, DOI: 10.1016/j.psychres.2023.115143.Peer-Reviewed Original ResearchConceptsHealthy controlsSmoking behaviorPsychotic symptomsSchizophrenia symptomsUnaffected siblingsProspective cohort studySix-year followMental health symptomsSymptom dimensionsCohort studyRisk factorsDepressive symptomsPsychotic disordersPatientsPositive symptomsHealth symptomsNegative symptomsSimilar effect sizesSymptomsLinear mixed-effects modelsMixed-effects modelsGenetic riskMean numberPolygenic scoresOverall sample
2022
Longitudinal alterations in mRNA expression of the BDNF neurotrophin signaling cascade in blood correlate with changes in depression scores in patients undergoing electroconvulsive therapy
Schurgers G, Walter S, Pishva E, Guloksuz S, Peerbooms O, Incio L, Arts B, Kenis G, Rutten B. Longitudinal alterations in mRNA expression of the BDNF neurotrophin signaling cascade in blood correlate with changes in depression scores in patients undergoing electroconvulsive therapy. European Neuropsychopharmacology 2022, 63: 60-70. PMID: 36067540, DOI: 10.1016/j.euroneuro.2022.07.183.Peer-Reviewed Original ResearchConceptsBrain-derived neurotrophic factorBDNF/TrkBExpression of BDNFSerum BDNF protein levelsBDNF protein levelsElectroconvulsive therapyDepression scoresMRNA expressionPeripheral bloodTreatment-resistant depressed patientsProtein levelsMechanism of actionAntidepressant effectsNeurotrophic factorDepressed patientsLongitudinal alterationsSevere depressionBlood correlatesEffective treatmentLongitudinal changesTrkBStudy periodNR3C1PatientsTherapyThe association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study
Fusar-Poli L, Pries LK, van Os J, Radhakrishnan R, Pençe AY, Erzin G, Delespaul P, Kenis G, Luykx JJ, Lin BD, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran EŞ, Kaymak SU, Mihaljevic MM, Andric-Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşoğlu C, Üçok A, Alptekin K, Saka MC, investigators G, Aguglia E, Arango C, Rutten BP, Guloksuz S. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Neuropsychopharmacology 2022, 63: 47-59. PMID: 36055075, DOI: 10.1016/j.euroneuro.2022.08.003.Peer-Reviewed Original ResearchConceptsHealthy controlsCannabis useDegraded Facial Affect Recognition TaskPresent cross-sectional studyCross-sectional studyHigh genetic riskProgression of schizophreniaRegular cannabis useCognitive disturbancesRegular cannabisPsychosis riskPatientsSchizophreniaFacial emotion recognition performanceGenetic riskCannabisCurrent cannabisEUGEI studyLongitudinal studyAgeSiblingsAssociationRiskOnsetEffect relationship
2021
Impact of the first COVID-19 outbreak on mental health service utilisation at a Dutch mental health centre: retrospective observational study
Chow M, Noorthoorn E, Wierdsma A, van der Horst M, de Boer N, Guloksuz S, Luykx J. Impact of the first COVID-19 outbreak on mental health service utilisation at a Dutch mental health centre: retrospective observational study. BJPsych Open 2021, 7: e213. PMID: 34784994, PMCID: PMC8632375, DOI: 10.1192/bjo.2021.1049.Peer-Reviewed Original ResearchMental health service utilisationHealth service utilisationService utilisationFirst COVID-19 outbreakCare contactsPatient contactPsychotic disordersVideo consultationsCOVID-19 outbreakDiagnostic categoriesRetrospective observational studyMental healthcare deliveryMental health centersCOVID-19 pandemicDifferent diagnostic categoriesPre-pandemic periodRetrospective studyHealth centersObservational studyMental illnessPatientsHealthcare deliveryHealthcare institutesTelepsychiatryCOVID-19 lockdownRisk profiles for mental disorders
Gülöksüz S. Risk profiles for mental disorders. European Psychiatry 2021, 64: s71-s71. PMCID: PMC9471330, DOI: 10.1192/j.eurpsy.2021.220.Peer-Reviewed Original ResearchPsychiatric diagnosisSame psychiatric diagnosisDifferent psychiatric diagnosesSame treatment protocolClinical staging modelRisk profilingDiagnosis-specific treatmentsSame treatment planTreatment protocolTreatment responseMedical conditionsClinical practiceDiagnostic classification systemsTreatment planMental disordersStaging modelRisk profileDiscrete diagnostic categoriesPatientsDiagnostic categoriesClinical predictionDiagnosisEarly psychopathologyTraditional diagnostic boundariesPrognosticationAssociation of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings
Noyan H, Erdağ E, Tüzün E, Yaylım İ, Küçükhüseyin Ö, Hakan M, Gülöksüz S, Rutten B, Saka M, Atbaşoğlu C, Alptekin K, van Os J, Üçok A. Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings. Schizophrenia Research 2021, 229: 27-37. PMID: 33609988, DOI: 10.1016/j.schres.2021.01.014.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersIL-1β levelsKYNA levelsHigher serum IL-1β levelsSerum IL-1β levelsHigher KYNA levelsTrp-Kyn pathwayKynurenic acid levelsSimilar clinical featuresPathophysiology of schizophreniaManifestations of schizophreniaKYN levelsSerum interleukinClinical featuresInflammatory cytokinesIL-1βClinical dataKynurenine pathwayTRP levelsSpectrum disorderControl groupAdvanced stageLow TrpPathway dysregulationPatientsAntipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis
Bak M, Drukker M, Cortenraad S, Vandenberk E, Guloksuz S. Antipsychotics result in more weight gain in antipsychotic naive patients than in patients after antipsychotic switch and weight gain is irrespective of psychiatric diagnosis: A meta-analysis. PLOS ONE 2021, 16: e0244944. PMID: 33596211, PMCID: PMC7888647, DOI: 10.1371/journal.pone.0244944.Peer-Reviewed Original ResearchConceptsAntipsychotic-naive patientsBody weight changesBody weight gainWeight gainPsychiatric diagnosisNaive patientsWeight changeAntipsychotic useBodyweight gainAntipsychotic-naive groupMore weight gainDiagnosis of schizophreniaAntipsychotic switchMost antipsychoticsShort followSwitch studyMetabolic disturbancesClinical trialsOutcome measuresAntipsychoticsPatientsBody weightNaive groupSwitch groupDiagnosis
2020
Phenome-wide and genome-wide analyses of quality of life in schizophrenia
Pazoki R, Lin B, van Eijk K, Schijven D, de Zwarte S, Alizadeh B, van Amelsvoort T, Bartels-Velthuis A, van Beveren N, Bruggeman R, Cahn W, de Haan L, Delespaul P, Luykx J, Myin-Germeys I, Kahn R, Schirmbeck F, Simons C, van Os J, van Winkel R, Guloksuz S, Luykx J. Phenome-wide and genome-wide analyses of quality of life in schizophrenia. BJPsych Open 2020, 7: e13. PMID: 33295273, PMCID: PMC7791571, DOI: 10.1192/bjo.2020.140.Peer-Reviewed Original ResearchPolygenic risk scoresRisk scoreClinical phenotypeNon-genetic contributing factorsMajor depressive disorderQuality of lifeDepressive disorderHealthy controlsVulnerable patientsStudy populationHypothesis-generating approachPatientsPsychotic disordersQoLSmall studyClinical interventionsSchizophreniaGenotypic determinantsScoresContributing factorDisordersPhenotypeAssociationEvidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway
van Os J, Pries L, Have M, de Graaf R, van Dorsselaer S, Delespaul P, Bak M, Kenis G, Lin B, Luykx J, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Mezquida G, Amoretti S, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Aguilar E, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Rutten B, Guloksuz S. Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. Psychological Medicine 2020, 52: 1910-1922. PMID: 33070791, DOI: 10.1017/s0033291720003748.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersChildhood adversityRisk factorsNEMESIS-2Affective dysregulationNon-genetic risk factorsSignificant depressive symptomsSample of patientsRepresentative general population sampleGenetic risk factorsGeneral population sampleSchizophrenia polygenic riskPsychosis outcomesSpectrum disorderDepressive symptomsPRS-SZPolygenic riskDysregulationPatientsPopulation samplePsychosisAffective pathwayDisordersHallucinatory experiencesDelusional ideationMinor Physical Anomalies in Bipolar Disorder
İnce B, Altinoz M, Ayran A, Cansız A, Altinbaş K, Guloksuz S, Kurt E. Minor Physical Anomalies in Bipolar Disorder. Comprehensive Psychiatry 2020, 103: 152206. PMID: 33099105, DOI: 10.1016/j.comppsych.2020.152206.Peer-Reviewed Original ResearchConceptsBipolar disorderMinor physical anomaliesBD patientsHealthy subjectsHigh arched palatePhysical anomaliesAuricular anomaliesPsychiatric disordersCleft lipPathogenesis pathwaysPatientsMinor anomaliesDeletion syndromeDisordersSecond pharyngeal archesDorsal endPalateSchizophreniaRegression modelsAuriclePharyngeal archesFirst pharyngeal archArchNew endophenotypesSubjects
2019
Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study
van Os J, Pries L, Delespaul P, Kenis G, Luykx J, Lin B, Richards A, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak S, Mihaljevic M, Petrovic S, Mirjanic T, Bernardo M, Cabrera B, Bobes J, Saiz P, García-Portilla M, Sanjuan J, Aguilar E, Santos J, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric N, Atbaşoğlu C, Ucok A, Alptekin K, Saka M, Arango C, O'Donovan M, Rutten B, Guloksuz S. Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study. Psychological Medicine 2019, 50: 1884-1897. PMID: 31414981, DOI: 10.1017/s003329171900196x.Peer-Reviewed Original ResearchConceptsPsychotic disordersPolygenic riskSchizophrenia polygenic riskGene-environment interactionsGenetic riskRelatives of patientsFirst-degree relativesPsychosis phenotypeAverage genetic riskIntermediate phenotypesHealthy siblingsCognitive intermediate phenotypesControl groupAnalysis of associationAverage riskPatientsPhenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort)
Pandit R, Cianci D, Hark S, Rossum I, Ebdrup B, Broberg B, Garcia‐Portilla M, Bobes J, Vinkers C, Kahn R, Guloksuz S, Huitema A, Luykx J. Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort). Acta Psychiatrica Scandinavica 2019, 140: 283-290. PMID: 31323113, PMCID: PMC6771865, DOI: 10.1111/acps.13074.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis patientsPsychosis patientsWeight gainSchizophreniform disorderAntipsychotic-induced weight gainFirst-episode patientsManagement of schizophreniaLower baseline weightMultivariable regression modelsWeight-reducing strategiesOptimization of treatmentRegression modelsMajor depression disorderPhenotypic factorsAmisulpride treatmentBaseline weightEurope (Syst-Eur) trialMost antipsychoticsDepression disorderYoung subjectsBody weightPatientsBetter efficacyYounger ageAIWGAffective Temperament and Seasonality in Bipolar Disorder.
Altınbaş K, İnce B, Gülöksüz S. Affective Temperament and Seasonality in Bipolar Disorder. Psychiatria Danubina 2019, 31: 106-110. PMID: 30948697, DOI: 10.24869/psyd.2019.106.Peer-Reviewed Original ResearchConceptsBipolar disorderIllness courseSeasonal Pattern Assessment QuestionnaireAffective temperamentsAnxious temperament scoresAssessment QuestionnaireEuthymic patientsTemperament scoresAffective temperament scoresTotal scoreMood regulationVersion scalePatientsScoresFurther investigationDisordersCourseEvidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia
Sahbaz C, Özer O, Kurtulmus A, Kırpınar I, Sahin F, Guloksuz S. Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia. Metabolic Brain Disease 2019, 34: 865-874. PMID: 30758707, DOI: 10.1007/s11011-019-00395-3.Peer-Reviewed Original ResearchConceptsBody mass indexSerum melatonin concentrationsPittsburgh Sleep Quality IndexHealthy controlsMelatonin concentrationsCognitive impairmentMorningness-Eveningness QuestionnaireHigher body mass indexLower MEQ scoresSleep Quality IndexNegative Syndrome ScaleEnzyme-linked immunosorbentCircadian preferenceMelatonin groupMass indexMelatonergic pathwaysHC groupPatientsNeurodevelopmental originSyndrome ScaleMelatonin levelsPatient samplesSchizophreniaMelatoninMEQ scoresPsychometric liability to psychosis and childhood adversities are associated with shorter telomere length: A study on schizophrenia patients, unaffected siblings, and non-clinical controls
Çevik B, Mançe-Çalışır Ö, Atbaşoğlu E, Saka M, Alptekin K, Üçok A, Sırmatel B, Gülöksüz S, Tükün A, van Os J, Gümüş-Akay G. Psychometric liability to psychosis and childhood adversities are associated with shorter telomere length: A study on schizophrenia patients, unaffected siblings, and non-clinical controls. Journal Of Psychiatric Research 2019, 111: 169-185. PMID: 30776705, DOI: 10.1016/j.jpsychires.2019.01.022.Peer-Reviewed Original ResearchConceptsShorter telomere lengthLonger telomere lengthChildhood adversityTelomere lengthUnaffected siblingsSCZ patientsChronic medical disordersCourse of schizophreniaSimilar telomere lengthPsychotic-like symptomsHypothesis patientsClinical presentationNon-clinical controlsMedical disordersGeneral populationFunctioning scoresPatientsSchizophrenia patientsSocio-demographic featuresGlobal assessmentEarly onsetSchizophreniaLife expectancyAges 0Potential role
2018
Evaluation of the Association between Lithium Treatment and GSK3β Polymorphism in Bipolar Disorder Patients.
Altınbaş K, Yeşilbaş D, İnce B, Cansız A, Sılan F, Özdemir Ö, Gülöksüz S. Evaluation of the Association between Lithium Treatment and GSK3β Polymorphism in Bipolar Disorder Patients. Turkish Journal Of Psychiatry 2018, 29: 73-78. PMID: 30215834, DOI: 10.5080/u20582.Peer-Reviewed Original ResearchConceptsMean ageLithium treatmentTreatment responseGSK-3βBipolar disorder type IBipolar disorder patientsLack of evidenceClinical predictorsHospital recordsTreatment adherenceTreatment optionsDisease onsetFirst episodeReal-time PCRIndividualized treatmentPharmacogenomic findingsBlood samplesDisorder patientsSide effectsAG genotypeClinical practiceScale scoreBipolar disorderPatientsSample cohort
2017
Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential
Altinoz M, Guloksuz S, Elmaci İ. Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential. Clinical And Translational Oncology 2017, 19: 785-792. PMID: 28093702, DOI: 10.1007/s12094-017-1613-6.Peer-Reviewed Original ResearchConceptsRabies virus vaccineImmune adjuvantsVirus vaccineGL261 mouse glioma modelNovel immune adjuvantsPilot clinical studyMouse glioma modelImmunotherapeutic modalitiesCervical cancerClinical studiesHealth StudyGlioblastoma patientsGlioma modelProtective roleLiterature searchCancerPublic health studiesRabies virusRemissionPatientsAdjuvantRelevant databasesRecent findingsInjectionKey words
2016
Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications
Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications. FOCUS The Journal Of Lifelong Learning In Psychiatry 2016, 14: 370-377. PMID: 31997958, PMCID: PMC6988756, DOI: 10.1176/appi.focus.140308.Peer-Reviewed Original Research
2015
Temperament characteristics in patients with panic disorder and their first-degree relatives
Altınbaş G, Altınbaş K, Gülöksüz S, Gülöksüz S, Aydemir Ö, Özgen G. Temperament characteristics in patients with panic disorder and their first-degree relatives. Comprehensive Psychiatry 2015, 60: 73-77. PMID: 25967357, DOI: 10.1016/j.comppsych.2015.03.008.Peer-Reviewed Original ResearchConceptsFirst-degree relativesHealthy controlsPanic disorderIrritable temperament scoresPanic Agoraphobia ScaleAnxious temperament scoresTemperament characteristicsTrait Anxiety InventoryClinical characteristicsPatient groupClinical conditionsSan Diego AutoquestionnairePatientsTemperament scoresTrait markerAgoraphobia ScaleAnxiety disordersProspective designDisordersStudy sampleHeritable anxiety disordersAnxiety InventoryTemperament EvaluationEducation levelIntermediate phenotypes